Status:
COMPLETED
Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis
Lead Sponsor:
FDA Office of Orphan Products Development
Conditions:
Amyloidosis
Phase:
PHASE2
Brief Summary
High-dose melphalan (MEL) with autologous stem cell transplant (SCT) is an effective therapy for systemic AL amyloidosis (AL), but treatment-related mortality (TRM) has historically been high. The inv...
Detailed Description
High-dose melphalan (MEL) with autologous stem cell transplant (SCT) is an effective therapy for systemic AL amyloidosis (AL), but treatment-related mortality (TRM) has historically been high. The inv...
Eligibility Criteria
Inclusion
Exclusion
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01527032
Start Date
September 1 2002
End Date
September 1 2005
Last Update
March 25 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.